BUSINESSDEUTSCHE WELLE
Why is the US targeting Germany's drug industry?
A new trade probe by the US is reigniting a dispute over cost distribution for medical innovation, with Washington claiming Germany benefits from lower drug prices while US patients cover higher costs.
Related Signal
Adjacent reporting
- US launches trade investigation into Germany’s spending on new medicines
- US launches Germany pharma pricing probe, raising threat of new tariffs
- STAT+: Pharmalittle: We’re reading about U.S. pressuring Germany on drug prices, FDA upheaval and biotech clinical trials, and more
- STAT+: As the U.S. looks on, European countries feel growing pressure on drug prices